{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:59Z","timestamp":1793386799834,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006418","name":"Brown University","doi-asserted-by":"publisher","award":["R25AI140490"],"award-info":[{"award-number":["R25AI140490"]}],"id":[{"id":"10.13039\/100006418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019399","name":"Viracor Eurofins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.diagmicrobio.2023.116139","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T23:29:37Z","timestamp":1700177377000},"page":"116139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Using a commercially available assay that measures cytomegalovirus (CMV)-specific T-cell immunity to predict protection against CMV: A prospective, blinded clinical study"],"prefix":"10.1016","volume":"108","author":[{"given":"Nouf K.","family":"Almaghlouth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Arvanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8489-108X","authenticated-orcid":false,"given":"Dimitrios","family":"Farmakiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0001","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/649903","article-title":"Cytomegalovirus reinfections in healthy seroimmune women","volume":"201","author":"Ross","year":"2010","journal-title":"J Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"AST infectious diseases community of practice. Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transpl"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.116139_bib0003","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0004","first-page":"e13977","article-title":"Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the international CMV symposium 2021","volume":"24","author":"Kotton","year":"2022"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.idcr.2017.01.001","article-title":"Rhomboid glossitis in disseminated CMV infection","volume":"8","author":"Black","year":"2017","journal-title":"IDCases"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2023.116139_bib0008","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cmi.2015.05.016","article-title":"Symptomatic cytomegalovirus gastrointestinal infection with positive quantitative real-time PCR findings in apparently immunocompetent patients: a case series","volume":"21","author":"Bernard","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2023.116139_bib0009","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/cid\/cix696","article-title":"Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"65","author":"Gardiner","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0010","article-title":"Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update","volume":"11","author":"Prakash","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"16","key":"10.1016\/j.diagmicrobio.2023.116139_bib0011","doi-asserted-by":"crossref","first-page":"e15228","DOI":"10.1097\/MD.0000000000015228","article-title":"Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article","volume":"98","author":"Ruan","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.116139_bib0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0013","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.116139_bib0014","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transpl"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.116139_bib0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01040-17","article-title":"Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: Clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection","volume":"56","author":"Chiereghin","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12879-018-3075-z","article-title":"Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients","volume":"18","author":"Deborska-Materkowska","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0018","first-page":"554","article-title":"Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia","volume":"50","author":"Thompson","year":"2018","journal-title":"Pathology (Phila)"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0019","doi-asserted-by":"crossref","first-page":"e12934","DOI":"10.1111\/tid.12934","article-title":"Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation","volume":"20","author":"Sood","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0020","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.116139_bib0021","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-gamma release assay in kidney transplant recipients treated with antithymocyte globulin","volume":"20","author":"Fernandez-Ruiz","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J Clin Virol"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.116139_bib0023","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.116139_bib0024","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/JCM.06406-11","article-title":"Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection","volume":"50","author":"Abate","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jcv.2014.09.015","article-title":"Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients","volume":"61","author":"Costa","year":"2014","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.116139_bib0026","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/tid.12509","article-title":"Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation","volume":"18","author":"Leone","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2023.116139_bib0027","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.116139_bib0028","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.transproceed.2017.07.001","article-title":"Enzyme-linked immunospot assay as a complementary method to assess and monitor cytomegalovirus infection in kidney transplant recipients on pre-emptive antiviral therapy: a single-center experience","volume":"49","author":"Favi","year":"2017","journal-title":"Transpl Proc"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0029","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tri.13110","article-title":"Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study","volume":"31","author":"Banas","year":"2018","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193968","article-title":"Assessment of the T-SPOT.CMV interferon-gamma release assay in renal transplant recipients: a single center cohort study","volume":"13","author":"Chanouzas","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2023.116139_bib0031","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+\/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.116139_bib0032","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transpl"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.116139_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2023.116139_bib0034","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1128\/JVI.78.11.5535-5545.2004","article-title":"Memory CD8 T-cell differentiation during viral infection","volume":"78","author":"Wherry","year":"2004","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.116139_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106044","article-title":"Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients","volume":"9","author":"Gabanti","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.116139_bib0036","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.15866","article-title":"CMV cell-mediated immunity assays: focus on CD4(+) cells","volume":"20","author":"Lerner","year":"2020","journal-title":"Am J Transpl"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0037","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.1093\/ofid\/ofx163.1620","article-title":"T-cell immunity panel measures CMV-specific CD4+ and CD8+ responses","volume":"4","author":"Lutgen","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0038","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12879-020-4787-4","article-title":"Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events","volume":"20","author":"Rogers","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0039","doi-asserted-by":"crossref","first-page":"e13311","DOI":"10.1111\/tid.13311","article-title":"Prediction of cytomegalovirus infection: A single-center experience utilizing a newly available cell-mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity","volume":"22","author":"Jorgenson","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0040","doi-asserted-by":"crossref","unstructured":"Jorgenson E.M., J. Descourouez, D. Mandelbrot, J. Smith, C. Saddler, J. Odorico. Real-world experience with CMV Insight T cell immunity testing in kidney and pancreas transplant recipients. American Transplant Congress (ATC) 2023.","DOI":"10.1177\/10600280231207899"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0041","unstructured":"Barnes A.K.S., Baddley J., Prakash K. Use of a CMV-specific T cell immunity panel (TCIP) to guide secondary prophylaxis after CMV infection. American Transplant Congress (ATC) 2023."},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0042","unstructured":"Servais A.M.J., Bowen R., Kleiboeker S., Miller M., Duncan K., Miles C. Tailoring CMV prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of CMV. Cutting Edge of Transplantation 2022."},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.116139_bib0043","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/15269248211046037","article-title":"Low-dose valganciclovir prophylaxis is safe and cost-saving in CMV-seropositive kidney transplant recipients","volume":"31","author":"Shi","year":"2021","journal-title":"Prog Transpl"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0044","doi-asserted-by":"crossref","first-page":"ofx143","DOI":"10.1093\/ofid\/ofx143","article-title":"Comparison of standardized cytomegalovirus (CMV) viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease","volume":"4","author":"Dioverti","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0045","unstructured":"Hixson J.G., Dann J., Medler C., Parpia T., Sharma B., Doyle A., et\u00a0al. Low-level asymptomatic cytomegalovirus viremia after prophylaxis can be safely monitored in kidney transplant recipients. American Transplant Congress (ATC) 2023."},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0046","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1111\/tid.12873","article-title":"Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation","volume":"20","author":"Serrano-Alonso","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.116139_bib0047","doi-asserted-by":"crossref","first-page":"e13051","DOI":"10.1111\/tid.13051","article-title":"Potential mortality benefit from secondary prophylaxis following CMV treatment completion may be due to confounding by transplant organ type","volume":"21","author":"Gardiner","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0048","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1399-3062.2012.00723.x","article-title":"Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis","volume":"14","author":"Wiita","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0049","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.mayocp.2018.09.017","article-title":"Application of a new paradigm for cytomegalovirus disease prevention in Mayo clinic's first face transplant","volume":"94","author":"Razonable","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.116139_bib0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.116139_bib0051","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.116139_bib0052","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.116139_bib0053","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diagmicrobio.2023.116139_bib0054","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","author":"Limaye","year":"2023","journal-title":"JAMA"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323002481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323002481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:59:28Z","timestamp":1760003968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889323002481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0732889323002481"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.116139","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using a commercially available assay that measures cytomegalovirus (CMV)-specific T-cell immunity to predict protection against CMV: A prospective, blinded clinical study","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.116139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116139"}}